Ersin AKARSU, Hakan KORKMAZ, Nurten AKSOY, Mesut ÖZKAYA, Suzan TABUR, Şefika Nur AKSOY, Esen SAVAŞ

Evaluation of Serum S100A8/S100A9 Levels in Patients with Autoimmune Thyroid Diseases

Background: The correlation of S100A8/S100A9 with various inflammatory conditions, including autoim-mune diseases have been reported. There is no study investigating the levels of S100A8/S100A9 in autoim-mune thyroid diseases (AITD)Aims: We aimed to evaluate the level of serum S100A8/S100A9 in AITD.Study Design: Case control study.Methods: Fifty patients with AITD (25 Hashimoto's thyroiditis (HT) and 25 Graves' disease (GD)) were included in the study. Twenty seven healthy subjects participated as a control group. Blood samples were obtained in the 3 months after the initiation of medi-cal treatment. Serum levels of total antioxidant status (TAS), total oxidative status (TOS), total free sulfhy-dryl (SH), lipid hydroperoxide (LOOH) and S100A8/S100A9 were analyzed. Results: The patients with AITD had significantly higher S100A8/S100A9, OSI, LOOH and TOS levels than the healthy control group. There was no signifi-cant difference between GD and HT patients in terms of S100A8/S100A9, TOS and OSI levels. S100A8/S100A9 level was positively correlated with LOOH, TOS and OSI levels but negatively correlated with -SH level in the patients with AITD.Conclusion: Serum S100A8/S100A9 levels were increased in patients with AITD and positively correlated with LOOH, TOS and OSI whereas negatively correlated with SH

PDF

___

Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev 2015;14:174-180. [CrossRef]
Zarkovic M. The role of oxidative stress on the pathogenesis of graves' disease. J Thyroid Res 2012;2012:302537 [CrossRef]
Marcocci C, Leo M, Altea MA. Oxidative stress in graves' dise- ase. Eur Thyroid J 2012;1:80-7. [CrossRef]
Rostami R, Aghasi MR, Mohammadi A, Nourooz-Zadeh J. Enhanced oxidative stress in Hashimoto's thyroiditis: inter- relationships to biomarkers of thyroid function. Clin Biochem 2013;46:308-12. [CrossRef]
Stríz I, Trebichavsky I. Calprotectin- a pleiotropic molecule in acute and chronic inflammation. Physiol Res 2004;53:245-53.
Schiopu A, Cotoi OS. S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease. Mediators Inflamm 2013;2013:828354. [CrossRef]
Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J. The endo- genous Toll-like receptor 4 agonist S100A8/S100A9 (calprotec- tin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009;86:557-66. [CrossRef]
van Bon L, Cossu M, Loof A, Gohar F, Wittkowski H, Vonk M, et al. Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic scle- rosis phenotype. Ann Rheum Dis 2014;73:1585-9. [CrossRef]
Lin JF, Chen JM, Zuo JH, Yu A, Xiao ZJ, Deng FH, et al. Me- ta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014;20:1407-15. [CrossRef]
García-Arias M, Pascual-Salcedo D, Ramiro S, Ueberschlag ME, Jermann TM, Cara C, et al. Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort. Mol Diagn Ther 2013;17:49-56. [CrossRef]
Andrés Cerezo L, Mann H, Pecha O, Plestilová L, Pavelka K, Vencovsky J, et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 2011;13:R122. [CrossRef]
Hurnakova J, Zavada J, Hanova P, Hulejova H, Klein M, Mann H, et al. Serum calprotectin (S100A8/9): an independent predic- tor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Res Ther 2015;17:252 [CrossRef]
Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112-9. [CrossRef]
Erel O. A new automated colorimetric method for measuring to- tal oxidant status. Clin Biochem 2005;38:1103-11. [CrossRef]
Arab K, Steghens JP. Plasma lipid hydroperoxides measure- ment by an automated xylenol orange method. Anal Biochem 2004;325:158-63. [CrossRef]
Aycicek A, Erel O, Kocyigit A. Increased oxidative stress in in- fants exposed to passive smoking. Eur J Pediatr 2005;164:775- 8. [CrossRef]
Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-7. [CrossRef]
Lassoued S, Mseddi M, Mnif F, Abid M, Guermazi F, Masmoudi H, et al. A comparative study of the oxidative profile in Graves' disease, Hashimoto's thyroiditis, and papillary thyroid cancer. Biol Trace Elem Res 2010;138:107-15. [CrossRef]
Erdamar H, Demirci H, Yaman H, Erbil MK, Yakar T, Sancak B, et al. The effect of hypothyroidism, hyperthyroidism, and their treatment on parameters of oxidative stress and antioxidant sta- tus. Clin Chem Lab Med 2008;46:1004-10. [CrossRef]
Komosinska-Vassev K, Olczyk K, Kucharz EJ, Marcisz C, Winsz-Szczotka K, Kotulska A. Free radical activity and an- tioxidant defense mechanisms in patients with hyperthyroi- dism due to Graves' disease during therapy. Clin Chim Acta 2000;300:107-17. [CrossRef]
Baser H, Can U, Baser S, Yerlikaya FH, Aslan U, Hidayetog- lu BT. Assesment of oxidative status and its association with thyroid autoantibodies in patients with euthyroid autoimmune thyroiditis. Endocrine 2015;48:916-23. [CrossRef]
Hansson C, Eriksson C, Alenius GM. S100A8/S100A9: a poten- tial marker of inflammation in patients with psoriatic arthritis. J Immunol Res 2014;2014:696415. [CrossRef]
Oktayoglu P, Bozkurt M, Mete N, Caglayan M, Em S, Nas K. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its associ- ation with disease activity and quality of life. J Investig Med 2014;62:880-4. [CrossRef]
Tydén H, Lood C, Gullstrand B, Jönsen A, Nived O, Sturfelt G, et al. Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inac- tive systemic lupus erythematosus. Rheumatology (Oxford) 2013;52:2048-55. [CrossRef]
van Bon L, Cossu M, Loof A, Gohar F, Wittkowski H, Vonk M, et al. Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic scle- rosis phenotype. Ann Rheum Dis 2014;73:1585-9. [CrossRef]
Poncin S, Van Eeckoudt S, Humblet K, Colin IM, Gérard AC. Oxidative stress: a required ondition for thyroid cell proliferati- on. Am J Pathol 2010;176:1355-63. [CrossRef]
Lim SY, Raftery MJ, Goyette J, Hsu K, Geczy CL. Oxidative modifications of S100 proteins: functional regulation by redox. J Leukoc Biol 2009;86:577-87. [CrossRef]
Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Pro- inflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Im- munol 2003;170:3233-42. [CrossRef]